BioCentury on BioBusiness,
Table: Post-launch report
Back to the parent article
Monday, January 7, 2013
At least four drugs approved in 2011 - Eylea
aflibercept, Incivek telaprevir, Yervoy ipilimumab and Zytiga abiraterone
acetate - are anticipated to exceed $500 million in sales in 2012. Of those,
Incivek has already passed $1 billion. However, demand for the HCV drug
reversed course in 2012. In July 2012, Vertex Pharmaceuticals Inc.
(NASDAQ:VRTX) cited two factors for the decrease in the number of HCV patients
initiating Incivek treatment: doctors waiting for all-oral combination therapies;
and an increase in the number of HCV clinical trials (see BioCentury, Nov.
For the first nine months of 2012, Eylea sales were
$561.9 million. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), which
launched the drug in the U.S. for wet age-related macular degeneration (AMD) in
November 2011, saw its share price triple in 2012.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]